Scientific Reports
April 17, 2024
Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss et al.
56 citations
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic...
November 15, 2022
Jeffrey Guss, Robert Krause, Jordan Sloshower
preprint
This is the French translation of the Yale Manual for Psilocybin-Assisted Therapy of Depression. Le Manuel de Yale pour le traitement thérapeutique de la dépression assisté par la psilocybine fournit aux chercheurs et aux thérapeutes des méthodes, une structure et des domaines à prendre en compte concernant l'utilisation de la thérapie assistée par les psychédéliques dans le traitement du...
Clinical Case Studies
August 1, 2021
Mailae Halstead, Sara Reed, Robert Krause et al.
Current research suggests that ketamine-assisted psychotherapy has benefit for the treatment of mental disorders. We report on the results of ketamine-assisted intensive outpatient psychotherapeutic treatment of a client with treatment-resistant, posttraumatic stress disorder (PTSD) as a result of experiences of racism and childhood sexual abuse. The client’s presenting symptoms included...
August 13, 2020
Jeffrey Guss, Robert Krause, Jordan Sloshower
86 citations
preprint
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therapeutic framework for...
Journal of Contextual Behavioral Science
2020
Jordan Sloshower, Jeffrey Guss, Robert Krause et al.
168 citations
Abstract Psychedelic-assisted therapy is based on the premise that psychedelic substances can act as catalysts or adjuncts to psychotherapeutic processes. Recent clinical trials involving psychedelic-assisted therapy have generally employed a similar three-part structure consisting of preparation, support during the dosing sessions, and subsequent “integration.” However, the content of these...